Department of Cardiothoracic & Vascular Surgery, Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.
J Card Surg. 2022 Oct;37(10):3044-3049. doi: 10.1111/jocs.16799. Epub 2022 Jul 23.
More than every third patient experiences recurrent atrial fibrillation after surgical pulmonary vein ablation. However, it remains challenging to predict who will and who will not experience this event. Scoring systems containing baseline risk factors have been proposed as a complementary tool to identify patients at higher risk of experiencing atrial fibrillation recurrence. Therefore, the aim of this study was to assess the value of the scoring systems APPLE, CHA DS -VASc, and CHADS in predicting atrial fibrillation recurrence following surgical ablation.
In a retrospective study, we identified all patients undergoing concomitant pulmonary vein ablation during cardiac surgery. APPLE-, CHA DS -VASc-, and CHADS scores were calculated for each patient. Subsequently, the predictive value of the scoring systems on atrial fibrillation recurrence 3-12 months postablation was assessed using receiver operating characteristic curves and logistic regression analyses.
Receiver operating characteristic curves showed the superiority of the APPLE scoring system with an area under the curve of 0.690 compared to 0.571 for CHA DS -VASc and 0.569 for CHADS , p = .01. Using logistic regression analyses, APPLE and CHA DS -VASc were predictors of atrial fibrillation recurrence between 3- and 12 months after surgical ablation (odds ratio [OR] 1.93, 95% confidence interval [CI] 1.39-2.67, p < .01 and OR 1.17, 95% CI 1.01-1.36, p = .04, respectively).
The APPLE scoring system is superior to CHA DS -VASc and CHADS in predicting atrial fibrillation recurrence after surgical ablation. It can be used as a complementary tool to select the right candidates for surgical ablation and identify patients who need more frequent clinical and electrocardiogram controls.
超过三分之一的患者在接受肺静脉消融手术后会出现复发性心房颤动。然而,预测哪些患者会经历这种情况,哪些患者不会经历这种情况仍然具有挑战性。包含基线风险因素的评分系统已被提议作为一种辅助工具,以识别发生心房颤动复发风险较高的患者。因此,本研究旨在评估 APPLE、CHA DS -VASc 和 CHADS 评分系统在预测外科消融后心房颤动复发中的价值。
在一项回顾性研究中,我们确定了所有在心脏手术中同时接受肺静脉消融的患者。为每位患者计算 APPLE、CHA DS -VASc 和 CHADS 评分。随后,使用受试者工作特征曲线和逻辑回归分析评估评分系统对消融后 3-12 个月心房颤动复发的预测价值。
受试者工作特征曲线显示,与 CHA DS -VASc 的 0.571 和 CHADS 的 0.569 相比,APPLE 评分系统的优势更为明显,曲线下面积为 0.690,p=0.01。使用逻辑回归分析,APPLE 和 CHA DS -VASc 是手术消融后 3-12 个月心房颤动复发的预测因素(优势比 [OR] 1.93,95%置信区间 [CI] 1.39-2.67,p<0.01 和 OR 1.17,95% CI 1.01-1.36,p=0.04)。
APPLE 评分系统在预测外科消融后心房颤动复发方面优于 CHA DS -VASc 和 CHADS。它可以作为一种辅助工具,选择适合外科消融的合适患者,并识别需要更频繁临床和心电图监测的患者。